welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study
study id #: NCT01712152
condition: Carrier of Duchenne Muscular Dystrophy
Carriers of Duchenne muscular dystrophy (DMD) often have no severe symptoms of the scelet muscles, but they may develop a poor heart function due to the involvement of the heart muscle. Ultrasound of the heart is recommended, but it can detect a cardiac affection only after the heart has already become weaker. Cardiac magnetic resonance tomography can detect myocardial fibrosis already at preserved heart function and may facilitate early therapy. In our study, diagnosed carriers of DMD will undergo examinations of the heart by blood tests, EKG, heart ultrasound and magnetic resonance at enrollment and after one year in order to assess the extent of cardiac affection and its association with the clinical development.
mechanism of action: No pharmaceutical intervention
last updated: November 14, 2020
start date: October 2012
estimated completion: September 2015
phase of development: N/A
size / enrollment: 20
- T1 mapping [ Time Frame: 1 year ]
T1 mapping by MOLLI sequences will be performed and compared between study entry and one year follow-up
- left ventricular function [ Time Frame: 1 year ]
left ventricular function on MRI will be compared between study entry and one year follow-up
• Eligible Sexes: male
• Claustrophobia Excessive obesity to an extent where CMR cannot be performed Chronic renal failure with a GFR <30 ml/min/1,73m² Implanted pacemakers/defibrillators Severe arrhythmia Inability to cooperate during the CMR Known intolerance to gadolinium Positive pregnancy test Unable or unwilling to conform to the study protocol
A Device for Rapid, Painless, Bedside Muscle Evaluation of ChildrenThe purpose of this protocol is to perfo...
Exploratory Study of NS-065/NCNP-01 in DMDThis study is designed to assess the saf...
Whole Body Vibration Therapy in Boys With Duchenne Muscular DystrophyWhole-body vibration therapy (WBVT) is a...
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyThe study is to demonstrate non-inferior...
Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular DystrophyThe aim of this study, determining the f...
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dy...Background: Edasalonexent is an orally ...
Stem Cell Therapy in Duchenne Muscular DystrophyThe purpose of this study was to study t...
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
Clay Matthews Supports Duchenne Muscular Dystrophy and First Approved Treatmenthttps://www.youtube.com/watch?v=WPu5pGEF...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...